Home > Press > Fluorotronics’ Carbon-Fluorine Spectroscopy Platform Hailed by Royal Society of Chemistry
Abstract:
Peer reviewed article announces major scientific discovery in nanotechnology; Carbon-Fluorine Spectroscopy can improve and accelerate pharmaceutical and biomedical analyses by detecting, labeling and imaging Carbon-Fluorine (C-F) bonds
Fluorotronics, Inc., developer of a patented Carbon-Fluorine Spectroscopy platform technology, known as Spectro-Fluor, for molecular detection, measurement and imaging in nanotechnology, pharmaceutical and life science markets, today announced the publication of a ground breaking article: "Development of Carbon-Fluorine Spectroscopy for pharmaceutical and biomedical applications," in the Royal Society of Chemistry's Faraday Discussions[1]. The article was authored by Dr. Bouzid Menaa, Dr. Farid Menaa and Ms. Olga Sharts, distinguished nanotechnology and chemistry experts. Ms. Sharts is also the CEO and founder of Fluorotronics, Inc.
The global organofluorine industry is comprised of diversified markets, including a $1.6 trillion nanotechnology market[2], which produce and use Carbon-Fluorine (C-F) compounds, molecules, products and materials. These C-F materials require extensive analyses during product research, development, and production. Common analytical methods have traditionally involved molecular labeling with radioactive isotopes or fluorescent dyes, which have limited utility, selectivity, sensitivity, stability and often require expensive safety and precautionary measures. In contrast, Fluorotronics' Spectro-Fluor optical technology uses a family of proprietary devices called PLIRFA™ (Pulsed Laser Isochronic Raman and Fluorescence Apparatus) to measure and analyze compounds, molecules, products and materials that contain Carbon-Fluorine (C-F) bonds.
By discovering the characteristic optical signature of Carbon-Fluorine bonds in the fingerprint spectral area of compounds, molecules, products and materials, Fluorotronics' Spectro-Fluor technology delivers the following benefits:
• Identifies and eliminates failed drug candidates at an early stage of drug development
• Provides stable and robust assays, preventing false positive signals from assays
• Enables the ability to study tissues and other biological matters repetitively without losing samples
• Identifies several disease and pharmaceutical targets or bio-markers at the same time (multiplexing)
• Achieves fast results by allowing researchers to obtain data in 0.1 seconds per analysis
"The publication of our research in the Royal Society of Chemistry journal confirms the major impact our Spectro-Fluor optical Carbon-Fluorine Spectroscopy will have on pharmaceutical and biomedical industries," said Olga Sharts, CEO and founder, Fluorotronics. "This article demonstrates that our innovative method and technology will become the ‘gold standard' for pharmaceutical research, development and applications."
####
About Fluorotronics, Inc.
A pioneer in fluoroanalytical nanotechnology, Fluorotronics, Inc. is the first company to introduce and license a patented Carbon-Fluorine Spectroscopy platform technology, known as Spectro-Fluor, for the molecular detection, measurement and imaging of compounds, materials or molecules that contain Carbon-Fluorine (C-F) bonds. This disruptive technology utilizes a family of pulsed laser-based PLIRFA devices to non-invasively detect C-F bonds and taggants across the entire fluoroorganic industry. Fluorotronics provides efficient, integrated and cost-effective solutions that address the product lifecycle in nanotechnology, pharmaceutical and life science markets. For more information about Fluorotronics, please visit www.fluorotronics.com.
About Royal Society of Chemistry
The RSC is the largest organization in Europe for advancing the chemical sciences. Supported by a network of over 46,000 members worldwide and an internationally acclaimed publishing business, its activities span education and training, conferences and science policy, and the promotion of the chemical sciences to the public. RSC was formed in 1980 from the merger of the Chemical Society, the Royal Institute of Chemistry, the Faraday Society and the Society for Analytical Chemistry with a new Royal Charter and the dual role of learned society and professional body.
[1] Development of Carbon-Fluorine Spectroscopy for Pharmaceutical and Biomedical Applications Farid Menaa, Bouzid Menaa, Olga Sharts
Faraday Discuss., 2011, 149, 269
DOI: 10.1039/c005252c
[2] "Nanotechnology Market Forecast to 2013." ResearchandMarkets, 2011 www.researchandmarkets.com/reports/888573/nanotechnology_market_forecast_to_2013.
For more information, please click here
Contacts:
Jessica Anderson
(415) 817-2596
Copyright © Fluorotronics, Inc.
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
Chemistry
Breaking carbon–hydrogen bonds to make complex molecules November 8th, 2024
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Patents/IP/Tech Transfer/Licensing
Getting drugs across the blood-brain barrier using nanoparticles March 3rd, 2023
Metasurfaces control polarized light at will: New research unlocks the hidden potential of metasurfaces August 13th, 2021
Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||